Publications

Authors:

Di Filippo, Massimiliano; Ferraro, Diana; Ragonese, Paolo; Prosperini, Luca; Maniscalco, Giorgia Teresa; Gallo, Antonio; Cavalla, Paola; Lorefice, Lorena; Nociti, Viviana; Di Sabatino, Elena; Clerico, Marinella; Guaschino, Clara; Radaelli, Marta; Fantozzi, Roberta; Buttari, Fabio; Laroni, Alice; Gajofatto, Alberto; Calabrese, Massimiliano; Malucchi, Simona; Paolicelli, Damiano; De Luca, Giovanna; Tomassini, Valentina; Lanzillo, Roberta; Moccia, Marcello; Solaro, Claudio; Cocco, Eleonora; Gasperini, Claudio; Tortorella, Carla

Title:

SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose

Year:

2024

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

A Stampa

Referee:

Sì

Name of journal:

Journal of Neurology

ISSN of journal:

0340-5354

N° Volume:

271

Number or Folder:

1

Page numbers:

24-31

Keyword:

COVID-19; Multiple sclerosis; SARS-CoV-2; Vaccination

Short description of contents:

Background: COVID-19 vaccines have been recommended to people with multiple sclerosis (pwMS) and, to ensure durable immunity, a third booster dose has been administered in several countries. Data about potential risks associated with the third booster dose in pwMS, such as vaccine-triggered disease exacerbations, are still scarce. Objective: To investigate whether the administration of a third booster dose of mRNA COVID-19 vaccines was associated with an increased risk of short-term disease reactivation in a large cohort of pwMS. Methods: We retrospectively selected 1265 pwMS who received a third booster dose of an mRNA COVID-19 vaccine. Demographic and clinical data were collected, including the presence, number and characteristics of relapses in the 60 days prior to and after the third booster dose. Results: In the selected cohort, the relapse rate in the two months after administration of the third booster dose of mRNA COVID-19 vaccines did not increase when compared with the prior two months. Indeed, the percentage of pwMS experiencing relapses in the 60 days following the administration of the third booster dose was 2.1%, similar to the percentage recorded in 60 days prior to vaccination, which was 1.9%. Conclusions: The third booster dose of mRNA COVID-19 vaccines appeared to be safe for pwMS.

Web page:

https://doi.org/10.1007/s00415-023-12034-0

Product ID:

136379

Handle IRIS:

11562/1114768

Last Modified:

January 26, 2024

Bibliographic citation:

Di Filippo, Massimiliano; Ferraro, Diana; Ragonese, Paolo; Prosperini, Luca; Maniscalco, Giorgia Teresa; Gallo, Antonio; Cavalla, Paola; Lorefice, Lorena; Nociti, Viviana; Di Sabatino, Elena; Clerico, Marinella; Guaschino, Clara; Radaelli, Marta; Fantozzi, Roberta; Buttari, Fabio; Laroni, Alice; Gajofatto, Alberto; Calabrese, Massimiliano; Malucchi, Simona; Paolicelli, Damiano; De Luca, Giovanna; Tomassini, Valentina; Lanzillo, Roberta; Moccia, Marcello; Solaro, Claudio; Cocco, Eleonora; Gasperini, Claudio; Tortorella, Carla, SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose «Journal of Neurology» , vol. 271 , n. 1 , 2024 , pp. 24-31

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo